Evidence map›Paper›PMID 35805892›Full record

ArticleInternational journal of molecular sciences2022

Katie S Ardipradja, Christian W Wichmann, Kevin Hickson, Angela Rigopoulos, Karen M Alt, Hannah A Pearce, Xiaowei Wang, Graeme O'Keefe, Andrew M Scott, Karlheinz Peter and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Site-specific bioconjugation and nuclear imaging.Current opinion in chemical biology · 2024
    Review
  3. Arginine-Selective Bioconjugation Reagent for EffectiveJournal of medicinal chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Katie S ArdipradjaDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Christian W WichmannDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Kevin HicksonDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Angela RigopoulosOlivia Newton-John Cancer Research Institute, La Trobe University, Melbourne 3086, Australia.
Karen M AltVascular Biotechnology Laboratory, Baker Heart and Diabetes Institute, Melbourne 3004, Australia.
Hannah A PearceVascular Biotechnology Laboratory, Baker Heart and Diabetes Institute, Melbourne 3004, Australia.
Xiaowei WangAtherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne 3004, Australia.ORCID 0000-0001-8658-7399
Graeme O'KeefeDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Andrew M ScottDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Karlheinz PeterAtherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne 3004, Australia.
Christoph E HagemeyerVascular Biotechnology Laboratory, Baker Heart and Diabetes Institute, Melbourne 3004, Australia.ORCID 0000-0002-7114-4023
Uwe AckermannDepartment of Molecular Imaging and Therapy, Austin Health, University of Melbourne, Heidelberg 3084, Australia.
Baker Heart and Diabetes Institute · AUThe University of Melbourne · AUCommonwealth Scientific and Industrial Research Organisation · AULa Trobe University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography is the imaging modality of choice when it comes to the high sensitivity detection of key markers of thrombosis and inflammation, such as activated platelets. We, previously, generated a fluorine-18 labelled single-chain antibody (scFv) against ligand-induced binding sites (LIBS) on activated platelets, binding it to the highly abundant platelet glycoprotein integrin receptor IIb/IIIa. We used a non-site-specific bio conjugation approach with

Indexed as

CysteineThrombosisAnimalsAntibodiesBlood PlateletsMaleimidesMicePositron-Emission TomographyTissue DistributionAntibodiesCysteineMaleimidesantibodiesFBEMPET/MRIplateletsthrombosis

Identifiers

PMID35805892
PMCPMC9267009
OpenAlexW4283276533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.